Kerry Hilton, HC&B HEALTHCARE COMMUNICATIONS
It used to be that sacrificing one's own health was not an option. So now new responsibility has emerged for marketers.
Kerry Hilton
PRESIDENT AND CEO | HC&B HEALTHCARE COMMUNICATIONS
It used to be that sacrificing one's own health was not an option. So now new responsibility has emerged for marketers. A new heightened need to educate is here. What are the benefits of sticking to your regimen? What are the dangers of stopping? How can you prioritize your lifestyle to put healthcare first? This dialogue can best be facilitated via the Web with accountability diaries that reward compliance or provide discounts. It's our responsibility to educate and encourage with new kinds of innovative communications.
Kerry Hilton
A much more stringent review of online messaging is most likely coming. Various rules will apply for display ads, rich media ads, banners, etc., depending on the real estate they occupy. I personally would like to see the industry step forward and lead this discussion with recommended guidelines now. This proactive approach will define the future rather than have it defined for us. Why not partner with Google? Let's merge together the future of online health with online health marketing.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
